The impacts of neoadjuvant chemotherapy and of cytoreductive surgery on 10-year survival from advanced ovarian cancer.
Soyoun Rachel KimJoanne KotsopoulosPing SunMarcus Q BernardiniStephane LaframboiseSarah E FergusonBarry RosenSteven A NarodTaymaa MayPublished in: International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics (2021)
Among women with advanced ovarian cancer, those who underwent primary cytoreductive surgery had better survival than those who received neoadjuvant chemotherapy. Neoadjuvant chemotherapy should be reserved for those in whom optimal primary cytoreductive surgery is not feasible.